1095272-10-8

Basic information

• Product Name: N-(benzo[d][1,3]dioxol-4-ylmethyl)-2-(3,4-dimethoxyphen-yl)-ethan-1-amine
• Synonyms: N-(benzo[d][1,3]dioxol-4-ylmethyl)-2-(3,4-dimethoxyphen-yl)-ethan-1-amine
• CAS NO: 1095272-10-8
• Molecular Weight: 315.369
• Mol File: 1095272-10-8.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: N-(benzo[d][1,3]dioxol-4-ylmethyl)-2-(3,4-dimethoxyphen-yl)-ethan-1-amine(CAS DataBase Reference)
• NIST Chemistry Reference: N-(benzo[d][1,3]dioxol-4-ylmethyl)-2-(3,4-dimethoxyphen-yl)-ethan-1-amine(1095272-10-8)
• EPA Substance Registry System: N-(benzo[d][1,3]dioxol-4-ylmethyl)-2-(3,4-dimethoxyphen-yl)-ethan-1-amine(1095272-10-8)

Safety Data

• Hazardous Substances Data: 1095272-10-8(Hazardous Substances Data)

Upstream product

• 120-57-0 piperonal 
• 139-85-5 3,4-dihydroxybenzaldehyde 
• 120-20-7 2-(3,4-dimethoxyphenyl)-ethylamine 
• 24677-78-9 2,3-dihydroxybenzaldehyde 
• 7797-83-3 2H-benzo[d]1,3-dioxolane-4-carbaldehyde 

Downstream Products

• 19716-60-0 8-oxo-epiberberine 
• 889665-86-5 epiberberine 

Relevant articles and documents

Total synthesis of epiberberine

Epiberberine, a natural bioactive protoberberine alkaloid, was totally synthesized in short, convenient and low-cost, four-step reactions including cyclization, condensation, reduction, and ring-closing, with an overall yield of 26.1%.

COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY

The present technology relates to methods of treating NASH, NAFLD and/or obesity using compounds of Formulas I, II, III, IV, V, and/or VI. The methods include administering to a subject suffering from one or more of non-alcoholic steatohepatitis (NASH), non- alcoholic fatty liver disease (NAFLD) and/or obesity a therapeutically effective amount of such a compound

CORYDALINE DERIVATIVES USEFUL FOR REDUCING LIPID LEVELS

The present technology relates to compounds of Formulas (V) and (VI) and methods of making and using such compounds. Methods of use include prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome. Compounds disclosed herein also lower total cholesterol, LDL- cholesterol, and triglycerides and increase hepatic LDL receptor expression, inhibit PCSK9 expression, and activate AMP-activated potein kinase.